{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"SIMONE","nct_id":"NCT06963905","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=simone-nct06963905. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SIMONE","arms":[{"description":"Sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab","label":"Arm A","type":"ACTIVE_COMPARATOR"},{"description":"Sacituzumab Govitecan plus nivolumab","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["Metastatic Triple-negative Breast Cancer"],"enrollment":{"count":60,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Relatlimab FDC + Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Sacituzumab Govitecan (SG)","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-22","lead_sponsor":"Yale University","official_title":"Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast Cancer","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2030-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence and severity of dose limiting toxicities in patients treated with sacituzumab govitecan combinations","timeFrame":"Three weeks post-Cycle 1 Day 1 (each cycle is 21 days)"}],"references":[],"start_date":{"date":"2025-12-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Saci Nivo Rela for TNBC","url":"https://clinicaltrials.gov/study/NCT06963905"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/simone-nct06963905"}